Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers
Gilead Sciences has collaborated with Strata Oncology to provide Trodelvy (Sacituzumab govitecan-hziy) for eligible cancer patients in the Strata Precision Indications for Approved THerapies (Strata PATH) trial.
ANN ARBOR, Mich., Jan. 18, 2023 /PRNewswire/ -- Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Gilead Sciences, Inc. has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™) trial by providing TRODELVY® (Sacituzumab govitecan-hziy) for eligible patients with cancer.
Pfizer and Strata Oncology have expanded their partnership for a clinical trial assessing various cancer therapies in new, biomarker-guided patient groups.
Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, has expanded its clinical collaboration with Pfizer in the Strata Precision Indications for Approved Therapies (Strata PATH) trial.
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Sarah Cannon...
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Lehigh Valley ...
ANN ARBOR, Mich., May 26, 2022 /PRNewswire/ -- Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that two new health system partners have joined the Strata Precision Indications for Approved THerapies (Strata PATH™) trial. The University of Wisconsin Carbone Cancer Center and the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham will join Ohio-based Kettering Health Cancer Center in bringing this innovative trial to both early-stage and late-stage patients with cancer.
ANN ARBOR, Mich., May 11, 2022 /PRNewswire/ -- Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced enrollment of the first patient in the Strata Precision Indications for Approved THerapies (Strata PATH™) trial, a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations.